方案摘要是疗程专着的缩写版本,仅包含有关用法,剂量,时间表,周期长度和特殊说明的顶级信息(如果有的话)。它旨在用于医疗保健提供者,仅用于信息目的。它不是构成或代替医疗建议的,并且该方案摘要的所有用途均经过临床判断。以“按原样”为基础提供此类信息,而无需任何表示,或暗示的,无论是明示的还是暗示的,法定的或其他方面的,也没有信息的质量,准确性,货币,完整性或可靠性,以及癌症护理Ontario不承担此信息的使用以及任何要求的索赔,动作,需求,需求或使用此类信息的全部责任。
LRITP LRITP O&M LRBP-MR LRBP-CD LRBP O&M 总计 A $22,653,700 $5,854,749 $11,705,000 $196,740,000 $1,170,525 $238,123,974 B $7,895,806 $1,942,605 $2,330,000 $15,200,000 $27,368,411 C $12,465,000 $1,900,000 $475,000 $138,560,000 $733,987 $154,133,987 D $4,735,135 $1,941,000 $8,580,000 $189,750,000 $1,450,000 $206,456,135 E $6,810,408 $2,319,446 $26,835,000 $130,750,000 $2,392,761 $169,107,615 总计 $54,560,049 $13,957,800 $49,925,000 $671,000,000 $5,747,273 $795,190,122
我们的系统专为人工智能驱动的HRBP设计。与通用的检索增强生成 (RAG) 解决方案不同,我们的系统提供针对HRBP的关注点、关注点和思维模式的定制洞察,使其与HRBP面临的挑战(包括其自身技能提升和在HR领域的职业发展)紧密契合。通过基于Lang Chain的智能代理,系统将引导HR专业人员逐步发现更深层次的问题,并对问题进行根本原因分析。这确保了对当前问题的全面理解。
关于稻米商业计划竞赛(RBPC)稻米商业计划竞赛(RBPC)是世界上最富有,最大的研究生级学生创业竞赛。它是由赖斯技术与企业家精神和莱斯大学的杰西·H·琼斯商学院主持和组织的。赖斯联盟是赖斯大学的国际认可的倡议,致力于支持企业家精神。这将是比赛的第25年!在那个时候,它已经从2001年争夺10,000美元的奖金的9支球队发展到来自世界各地的42支球队,争夺超过150万美元的现金和奖品。竞争旨在为大学企业家提供现实世界中的经验,以向投资者推销他们的初创企业,接收指导,与企业家生态系统建立联系,增强他们的创业策略,并了解开设成功的初创公司所需的方式。
Established in 1988 Andrew Lewis was appointed Laboratory Chief in 1997 Keith Peden was appointed Laboratory Chief in 2011 LDNAV was last reviewed in 2018 While the Lab was set up to review and study DNA viruses as vaccines or vaccine-vectored vaccines, its role has evolved to encompass other viruses and cell-substrate safety issues as priorities change and emergencies arise
AE adverse event AESI adverse event of special interest AIDS acquired immunodeficiency syndrome ARDS acute respiratory distress syndrome CBRN chemical, biological, radiological, or nuclear CDC Centers for Disease Control and Prevention EUA Emergency Use Authorization FDA Food and Drug Administration hACE2 human angiotensin converting enzyme 2 HHS Health and Human Services HIV human immunodeficiency virus IM intramuscular LNP脂质纳米粒子中东呼吸综合征mRNA Messenger RNA NAAT NAAT核酸扩增基于测试RT-PCR逆转录 - 转录 - 聚合酶链链反应SAE严重不良事件SARS-COV-SARS-COV-2严重急性急性呼吸道呼吸道综合征2 VE疫苗效应VRBPAC效应VRBPAC效果
Abbreviation Definition AE adverse event AESI adverse events of special interest BLA Biologics License Application BMI body mass index CDC US Centers for Disease Control CMC Chemistry, Manufacturing, and Control CoV Coronavirus 2019-nCoV 2019 novel Coronavirus COVID-19 Coronavirus Disease 2019 DART developmental and reproductive toxicity ELISpot enzyme-linked immunospot EUA Emergency Use Authorization FDA (US) Food and Drug Administration FIH first-in-human GMC geometric mean concentration GMFR geometric mean fold-rise GMT geometric mean titer HBV hepatitis B virus HCV hepatitis C virus HIV human immunodeficiency virus IFN γ interferon gamma IgG immunoglobulin G IL-2 interleukin 2 IL-4 interleukin 4 IM intramuscular(ly) IRR illness rate ratio LLN lower limit of normal LNP lipid nanoparticle MedDRA Medical Dictional for Regulatory Activities MERS Middle East respiratory syndrome modRNA nucleoside-modified RNA NAAT nucleic acid amplification test NHP nonhuman primate P2 S P2 mutant PBMC peripheral blood mononuclear cell PCR polymerase chain reaction PK药代动力学PT首选术语RBD受体结合结构域RNA RNA核糖酸RNA-LNP RNA RNA脂质纳米颗粒SAE SAE严重不良事件SARS严重急性呼吸综合症SARS-COV-2 SARS-COV-2 SARS COTORONAVIRUS-CORONAVIRUS-2;引起covid-19的病毒S尖峰糖蛋白SMQ标准化MEDDRA查询SOC系统器官类Th1 T辅助细胞类型1 TH2 T辅助细胞类型2美国美国USP美国Pharmacopeia